Melanoma/Skin Cancer

Top Story

Mohs micrographic surgery comparable to wide local excision for melanoma in situ

February 24, 2017

There were no significant differences in outcomes for patients with melanoma in situ who were treated with Mohs micrographic surgery compared with those treated with wide local excision, the current standard of care, according to study results published in JAMA Dermatology.

The researchers retrospectively reviewed a prospective database of 2,299 patients with a diagnosis of primary melanoma treated with either wide local excision (WLE) or Mohs micrographic surgery (MMS). Patients with invasive melanoma were excluded, and 662 patients were included in the study: 277 treated with MMS (mean age, 64 years; 62.1% male) and 385 treated with WLE (mean age, 58.5 year; 54.8% male).

Meeting News

Intratumoral therapy increases response to checkpoint inhibitor for melanoma

February 24, 2017
The phase 2 registration trial designed to evaluate ImmunoPulse IL-12 in combination with pembrolizumab for unresectable metastatic melanoma showed an increase in…

Improvements needed to better integrate PCPs into cancer survivorship care

February 24, 2017
Several cancer survivorship care models are available to help integrate primary care providers into the long-term follow-up care of cancer survivors. However, limited…
FDA News

FDA orders drug, dietary supplement maker to immediately cease operations

February 23, 2017
United States District Judge Robert G. James for the District Court for the Western District of Louisiana issued a consent decree of permanent injunction against Pick…
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video
Meeting News Coverage

VIDEO: Research into immunotherapy combinations makes ‘great strides’ at ESMO

October 28, 2016
More »
Featured
CME

Combination Strategies in Melanoma Management: What’s New and What’s Next

This activity is supported by an educational grant from Genentech, Inc.

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is…
More »
In the Journals

Mohs micrographic surgery comparable to wide local excision for melanoma in situ

February 24, 2017
There were no significant differences in outcomes for patients with melanoma in situ who were treated with Mohs micrographic surgery compared with…

Meeting News

Intratumoral therapy increases response to checkpoint inhibitor for melanoma

February 24, 2017
The phase 2 registration trial designed to evaluate ImmunoPulse IL-12 in combination with pembrolizumab for unresectable metastatic melanoma showed…

Improvements needed to better integrate PCPs into cancer survivorship care

February 24, 2017
Several cancer survivorship care models are available to help integrate primary care providers into the long-term follow-up care of cancer survivors…

FDA News

FDA orders drug, dietary supplement maker to immediately cease operations

February 23, 2017
United States District Judge Robert G. James for the District Court for the Western District of Louisiana issued a consent decree of permanent…

In the Journals Plus

Abbreviated high-dose interferon induction fails to prolong RFS in melanoma

February 23, 2017
Patients with surgically resected intermediate-level melanoma who received 4 weeks of high-dose IV interferon induction had identical RFS and OS…

Novel probe has potential to aid in margin detection during cancer surgery

February 22, 2017
Researchers in Australia have developed a novel optical fiber probe with high sensitivity for detecting and differentiating cancerous tissue from…

Many patients lack knowledge about advances in cancer diagnostics, treatment

February 22, 2017
A majority of patients with cancer and their caregivers lack sufficient knowledge about advances in diagnostic and treatment options, according to…

Supplement

Monoclonal antibodies show promise in treating solid tumors

HemOnc Today, February 25, 2017
Tremendous excitement currently surrounds the use of immuno-oncology agents for the treatment of various of solid tumors. Immuno-oncology treatments…

Meeting News

Diverse gut microbiome may improve response to immunotherapy for melanoma

February 21, 2017
Patients with melanoma who responded to immunotherapy had a more diverse gut microbiome than nonresponders, according to study results scheduled for…

In the Journals Plus

Many nonelderly cancer survivors alter prescription drug use to save money

February 21, 2017
Nearly one-third of nonelderly Americans recently diagnosed with cancer change their prescription drug use for financial reasons, according to an…

More Headlines »
Advertisement
Advertisement